drugset / Trial / NCT03145402
ICMNC-HF. IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients
Non-randomizedParallel-groupDouble-blindTreatment
Summary
This is a prospective, randomised double blind, controlled, parallel-group phase I and II study. Its aim is to assess that a single intracoronary infusion of autologous bone marrow-mononuclear cells is safe and effective in hear failure patients with reduced left ventricular ejection fraction(\<=30%) when compared to a control group of patients undergoing best medical care.
Timeline
- Start
- 2020-10-20
- Primary completion
- 2021-08-28
- Completion
- 2021-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous bone marrow-derived mononuclear cells | Cell therapy | — | Other |